Safety Study of Regorafenib and SIR-Spheres® Microspheres Radioembolization in Patients With Refractory Metastatic Colorectal Cancer With Liver Metastases
NCT ID: NCT02195011
Last Updated: 2023-12-05
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
26 participants
INTERVENTIONAL
2014-07-31
2017-06-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NON_RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort 1: Regorafenib/SIR-Spheres/Regorafenib
Regorafenib (one cycle) followed by SIR-Spheres followed by re-initiation of regorafenib 2-4 weeks after SIR-Spheres.
Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle. SIR-Spheres microspheres will then be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. Treatment with regorafenib will be re-started 2-4 weeks after SIR-Spheres administration.
SIR-Spheres
Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
Regorafenib
All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
Cohort 2: SIR-Spheres/Regorafenib
SIR-Spheres followed by regorafenib to start 2-4 weeks after SIR-Spheres.
SIR-Spheres microspheres will be administered to the patient by injection through a trans-femoral catheter into the hepatic artery. After SIR-Spheres microspheres have been administered, the treatment with regorafenib will be initiated 2-4 weeks after administration of SIR-Spheres. Patients will take regorafenib 160 mg orally once daily on Days 1-21 of each 28-day treatment cycle.
SIR-Spheres
Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
Regorafenib
All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SIR-Spheres
Radioembolization will be administered once by injection through a trans-femoral catheter into the hepatic artery.
Regorafenib
All patients will take regorafenib 160mg orally once daily on Days 1-21 of each 28-day cycle.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patients who have been previously treated with or are not candidates for fluorouracil, oxaliplatin, irinotecan, and if Kras wild-type, anti EGFR therapy.
3. Considered an appropriate candidate for regorafenib therapy.
4. Measurable disease or evaluable disease as measured by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1.
5. Measurable computed tomography (CT) scan evidence of liver metastases which are not treatable by surgical resection or local ablation with curative intent at the time of study entry.
6. ECOG Performance Status score of 0-1.
7. Adequate hematologic, renal and liver function.
8. Male patients with female partners of childbearing potential and women female patients of childbearing potential are required to use two forms of acceptable contraception, including one barrier method, during their participation in the study and for 30 days following last dose.
9. Life expectancy ≥ 3 months.
10. Ability to understand the nature of this study and give written informed consent
Exclusion Criteria
2. Use of a study drug ≤21 days or 5 half-lives (whichever is shorter) prior to initiation of study treatment. For study drugs for which 5 half-lives is ≤21 days, a minimum of 10 days between termination of the study drug and administration of study treatment is required.
3. Wide field radiotherapy (including therapeutic radioisotopes such as strontium-89 administered ≤28 days or limited field radiation for palliation ≤7 days prior to starting study drug or has not recovered from side effects of such therapy.
4. Previous radiation delivered to the upper abdomen.
5. Major surgical procedures ≤28 days of beginning study drug, or minor surgical procedures ≤7 days. No waiting required following port-a-cath placement.
6. Previously untreated brain metastases. Patients who have received radiation or surgery for brain metastases are eligible if therapy was completed at least 2 weeks previously and there is no evidence of central nervous system disease progression, mild neurologic symptoms, and no requirement for chronic corticosteroid therapy.
7. Leptomeningeal metastases or spinal cord compression due to disease.
8. Pregnant or lactating.
9. Evidence of ascites, cirrhosis, portal hypertension, or thrombosis as determined by clinical or radiologic assessment.
10. History of abdominal fistula or gastrointestinal perforation ≤6 months prior to beginning study treatment.
11. Serious non-healing wound, active ulcer, or untreated bone fracture.
12. Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism, or excretion of oral therapy (e.g. ulcerative disease, uncontrolled nausea, vomiting, diarrhea Grade ≥2, and malabsorption syndrome).
13. Any of the following cardiac diseases currently or within the last 6 months:
* Unstable angina pectoris
* Congestive heart failure (NYHA ≥ Grade 2)
* Conduction abnormality not controlled with pacemaker or medication
* Significant ventricular or supraventricular arrhythmias (patients with chronic rate-controlled atrial fibrillation in the absence of other cardiac abnormalities are eligible)
* Valvular disease with significant compromise in cardiac function
14. Inadequately controlled hypertension (i.e., systolic blood pressure \[SBP\] \>180 mmHg or diastolic blood pressure (DBP) \>100 mmHg) (patients with values above these levels must have their blood pressure (BP) controlled with medication prior to starting treatment).
15. Serious active infection at the time of treatment, or another serious underlying medical condition that would impair the ability of the patient to receive protocol treatment.
16. Known diagnosis of human immunodeficiency virus, hepatitis B, or hepatitis C.
17. Presence of other active cancers, or history of treatment for invasive cancer ≤5 years. Patients with Stage I cancer who have received definitive local treatment and are considered unlikely to recur are eligible. All patients with previously treated in situ carcinoma (i.e., non-invasive) are eligible, as are patients with history of non-melanoma skin cancer.
18. Use of strong CYP34A inducers or inhibitors.
19. The herbal medications St. John's wort, kava, ephedra (ma huang), gingko biloba, dehydroepiandrosterone (DHEA), yohimbe, saw palmetto, and ginseng will not be allowed during study treatment. Patients should stop using these herbal medications 7 days prior to first dose of study drug.
20. Psychological, familial, sociological, or geographical conditions that do not permit compliance with the protocol.
21. Inability or unwillingness to comply with study and/or follow-up procedures outlined in the protocol.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Sirtex Medical
INDUSTRY
SCRI Development Innovations, LLC
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Andrew Kennedy, MD
Role: STUDY_CHAIR
SCRI Development Innovations, LLC
Johanna Bendell, MD
Role: STUDY_CHAIR
SCRI Development Innovations, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Florida Cancer Specialists - North
St. Petersburg, Florida, United States
Research Medical Center
Kansas City, Missouri, United States
Tennessee Oncology PLLC
Nashville, Tennessee, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
SCRI GI 189
Identifier Type: -
Identifier Source: org_study_id